Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin

Hypertension

Volumn 54, Issue 6, 2009, Pages 1313-1320

  Tian, Jiang ^a   Shidyak, Amjad ^a   Periyasamy, Sankaridrug M ^a   Haller, Steven ^a   Taleb, Mohamed ^a   El Okdi, Nasser ^a   Elkareh, Jihad ^a   Gupta, Shalini ^a   Gohara, Sabry ^a   Fedorova, Olga V ^b   Cooper, Christopher J ^a   Xie, Zijian ^a   Malhotra, Deepak ^a   Bagrov, Alexei Y ^b   Shapiro, Joseph I ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Cardiomyopathy; Cardiotonic steroids; Collagen; Fibrosis; Renal failure

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CANRENONE; COLLAGEN; MARINOBUFAGENIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OUABAIN; PROCOLLAGEN; PROCOLLAGEN 1; PROLINE; PROTEIN KINASE C DELTA; SPIRONOLACTONE; UNCLASSIFIED DRUG; ALDOSTERONE ANTAGONIST; BUFADIENOLIDE DERIVATIVE; CARDIOTONIC AGENT; DIAGNOSTIC AGENT; TRITIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOMYOPATHY; CELL CULTURE; CELL STIMULATION; COLLAGEN SYNTHESIS; COMPETITIVE INHIBITION; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; FIBROBLAST; HEART MUSCLE FIBROSIS; HEART VENTRICLE PRESSURE; MALE; NEPHRECTOMY; NONHUMAN; PARTIAL NEPHRECTOMY; PRESSURE VOLUME CURVE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RAT; SIGNAL TRANSDUCTION; STAINING; UREMIC CARDIOMYOPATHY; WESTERN BLOTTING; ANIMAL; CYTOLOGY; DISEASE MODEL; DRUG INTERACTION; HEART MUSCLE; KIDNEY FAILURE; METABOLISM; PATHOLOGY; UREMIA;

ALDOSTERONE ANTAGONISTS; ANIMALS; BUFANOLIDES; CANRENONE; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; ENDOMYOCARDIAL FIBROSIS; FIBROBLASTS; KIDNEY FAILURE; MYOCARDIUM; NEPHRECTOMY; OUABAIN; PROCOLLAGEN; PROLINE; RATS; SPIRONOLACTONE; TRITIUM; UREMIA;

EID: 73349127049     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.140038     Document Type: Article

References (54)

1. Campbell SE, Janicki JS, Weber KT. Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. J Mol Cell Cardiol. 1995;27: 1545-1560
2. Fanestil DD. Mode of spirolactone action: competitive inhibition of aldosterone binding to kidney mineralocorticoid receptors. Biochem Pharmacol. 1968;17:2240-2242
3. Funder JW. Steroids, hypertension and cardiac fibrosis. Blood Press. 1995;2(suppl):39-42
4. Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol. 2009;54:505-512
5. Nehme JA, Lacolley P, Labat C, Challande P, Robidel E, Perret C, Leenhardt A, Safar ME, Delcayre C, Milliez P. Spironolactone improves carotid artery fibrosis and distensibility in rat post-ischaemic heart failure. J Mol Cell Cardiol. 2005;39:511-519
6. Taniguchi I, Kawai M, Date T, Yoshida S, Seki S, Taniguchi M, Shimizu M, Mochizuki S. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. Circ J. 2006;70:995-1000
7. Nakano S, Kobayashi N, Yoshida K, Ohno T, Matsuoka H. Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/salt-induced hypertensive rats. Hypertens Res. 2005;28:925-936
8. Sadee W, Abshagen U, Finn C, Rietbrock N. Conversion of spironolactone to canrenone and disposition kinetics of spironolactone and canrenoate-potassium in rats. Naunyn Schmiedebergs Arch Pharmacol. 1974;283:303-318
9. Karim A, Kook C, Zitzewitz DJ, Zagarella J, Doherty M, Campion J. Species differences in the metabolism and disposition of spironolactone. Drug Metab Dispos. 1976;4:547-555
10. Balzan S, Nicolini G, Bellitto L, Ghione S, Biver P, Montali U. Effect of canrenone on the digitalis site of Na+/K( + )-ATPase in human placental membranes and in erythrocytes. J Cardiovasc Pharmacol. 2003;42: 32-36
11. Finotti P, Palatini P. Canrenone as a partial agonist at the digitalis receptor site of sodium-potassium-activated adenosine triphosphatase. J Pharmacol Exp Ther. 1981;217:784-790
12. Barbato JC, Mulrow PJ, Shapiro JI, Franco-Saenz R. Rapid effects of aldosterone and spironolactone in the isolated working rat heart. Hypertension. 2002;40:130-135
13. Barbato JC, Rashid S, Mulrow PJ, Shapiro JI, Franco-Saenz R. Mechanisms for aldosterone and spironolactone-induced positive inotropic actions in the rat heart. Hypertension. 2004;44:751-757
14. Kennedy D, Omran E, Periyasamy SM, Nadoor J, Priyadarshi A, Willey JC, Malhotra D, Xie Z, Shapiro JI. Effect of chronic renal failure on cardiac contractile function, calcium cycling, and gene expression of proteins important for calcium homeostasis in the rat. J Am Soc Nephrol. 2003;14:90-97
15. Kennedy DJ, Vetteth S, Periyasamy SM, Kanj M, Fedorova L, Khouri S, Kahaleh MB, Xie Z, Malhotra D, Kolodkin NI, Lakatta EG, Fedorova OV, Bagrov AY, Shapiro JI. Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension. 2006;47:488-495
16. Elkareh J, Kennedy DJ, Yashaswi B, Vetteth S, Shidyak A, Kim EG, Smaili S, Periyasamy SM, Hariri IM, Fedorova L, Liu J, Wu L, Kahaleh MB, Xie Z, Malhotra D, Fedorova OV, Kashkin VA, Bagrov AY, Shapiro JI. Marinobufagenin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy. Hypertension. 2007;49: 215-224
17. Feria I, Pichardo I, Juarez P, Ramirez V, Gonzalez MA, Uribe N, Garcia-Torres R, Lopez-Casillas F, Gamba G, Bobadilla NA. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int. 2003;63:43-52
18. Kennedy DJ, Elkareh J, Shidyak A, Shapiro AP, Smaili S, Mutgi K, Gupta S, Tian J, Morgan E, Khouri S, Cooper CJ, Periyasamy SM, Xie Z, Malhotra D, Fedorova OV, Bagrov AY, Shapiro JI. Partial nephrectomy as a model for uremic cardiomyopathy in the mouse. Am J Physiol Renal Physiol. 2008;294:F450-F454
19. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol. 1994;26:809-820
20. Periyasamy SM, Liu J, Tanta F, Kabak B, Wakefield B, Malhotra D, Kennedy DJ, Nadoor A, Fedorova OV, Gunning W, Xie Z, Bagrov AY, Shapiro JI. Salt loading induces redistribution of the plasmalemmal Na/K-ATPase in proximal tubule cells. Kidney Int. 2005;67:1868-1877
21. Liang M, Tian J, Liu L, Pierre S, Liu J, Shapiro J, Xie ZJ. Identification of a pool of non-pumping Na/K-ATPase. J Biol Chem. 2007;282: 10585-10593
22. Elkareh J, Periyasamy SM, Shidyak A, Vetteth S, Schroeder J, Raju V, Hariri IM, El-Okdi N, Gupta S, Fedorova L, Liu J, Fedorova OV, Kahaleh MB, Xie Z, Malhotra D, Watson DK, Bagrov AY, Shapiro JI. Marinobu-fagenin induces increases in procollagen expression in a process involving protein kinase C and Fli-1: implications for uremic cardiomy-opathy. Am J Physiol Renal Physiol. 2009;296:F1219-F1226
23. London GM, Parfrey PS. Cardiac disease in chronic uremia: patho-genesis. Adv Ren Replace Ther. 1997;4:194-211
24. Burlew BS, Weber KT. Cardiac fibrosis as a cause of diastolic dysfunction. Herz. 2002;27:92-98
25. Vohringer M, Mahrholdt H, Yilmaz A, Sechtem U. Significance of late gadolinium enhancement in cardiovascular magnetic resonance imaging (CMR). Herz. 2007;32:129-137
26. Gross ML, Ritz E. Hypertrophy and fibrosis in the cardiomyopathy of uremia-beyond coronary heart disease. Semin Dial. 2008;21:308-318
27. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol. 1996;78:902-907
28. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717
29. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996;98:1063-1068
30. Funder JW. Aldosterone, salt and cardiac fibrosis. Clin Exp Hypertens. 1997;19:885-899
31. Okada T, Nagai M, Taniguchi I, Kuno M, Imamoto S, Seki S, Taniguchi M, Mochizuki S. Combined treatment with valsartan and spironolactone prevents cardiovascular remodeling in renovascular hypertensive rats. Int Heart J. 2006;47:783-793
32. Susic D, Varagic J, Ahn J, Matavelli L, Frohlich ED. Long-term miner-alocorticoid receptor blockade reduces fibrosis and improves cardiac performance and coronary hemodynamics in elderly SHR. Am J Physiol Heart Circ Physiol. 2007;292:H175-H179
33. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens. 2005;18:44-49
34. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med. 2006;119:912-919
35. Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, Fujita T. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol. 2006;17:3438-3446
36. Brilla CG. Aldosterone and myocardial fibrosis in heart failure. Herz. 2000;25:299-306
37. Zannad F, Radauceanu A. Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure. Heart Fail Rev. 2005;10:71-78
38. Sato A, Saruta T. Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res. 2004;27:303-310
39. Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res. 1994;28:1863-1867
40. Kohler E, Bertschin S, Woodtli T, Resink T, Erne P. Does aldosterone-induced cardiac fibrosis involve direct effects on cardiac fibroblasts? J Vasc Res. 1996;33:315-326
41. Lijnen P, Petrov V. Antagonism of the renin-angiotensin-aldosterone system and collagen metabolism in cardiac fibroblasts. Methods Find Exp Clin Pharmacol. 1999;21:215-227
42. Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol. 2000;32:865-879
43. Young MJ, Funder JW. Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system. J Hypertens. 2002;20:1465-1468
44. Funder JW. Minireview: aldosterone and the cardiovascular system: genomic and nongenomic effects. Endocrinology. 2006;147:5564-5567
45. Anderson DE, Fedorova OV, Morrell CH, Longo DL, Kashkin VA, Metzler JD, Bagrov AY, Lakatta EG. Endogenous sodium pump inhibitors and age-associated increases in salt sensitivity of blood pressure in normotensives. Am J Physiol Regul Integr Comp Physiol. 2008;294: R1248-R1254
46. Rostand SG, Drueke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int. 1999;56:383-392
47. Michea L, Villagran A, Urzua A, Kuntsmann S, Venegas P, Carrasco L, Gonzalez M, Marusic ET. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats. Hypertension. 2008;52:295-300
48. Selye H, Krajny M, Savoie L. Digitoxin poisoning: prevention by spironolactone. Science. 1969;164:842-843
49. Erdmann E, Krawietz W, Poppert D, Kruger R, von Arnim T, Vogt W, Bolte HD. Cardiac effects of antikaliuretic diuretics-clinical and biochemical investigation [in German]. Klin Wochenschr. 1977;55:985-994
50. Garay RP, Diez J, Nazaret C, Dagher G, Abitbol JP. The interaction of canrenone with the Na +,K+ pump in human red blood cells. Naunyn Schmiedebergs Arch Pharmacol. 1985;329:311-315
51. Sorrentino R, Cirino G, Calignano A, Mancuso F, Sorrentino L, Andriuoli G, Pinto A. Increase in the basal tone of guinea pig thoracic aorta induced by ouabain is inhibited by spironolactone canrenone and potassium can-renoate. J Cardiovasc Pharmacol. 1996;28:519-525
52. Miner PB Jr, Sneller M, Crawford SS. Spironolactone-and canrenone-induced changes in hepatic (Na +,K + )ATPase activity, surface membrane cholesterol and phospholipid, and fluorescence polarization in the rat. Hepatology. 1983;3:481-488
53. Wehling M, Kasmayr J, Theisen K. Rapid effects of mineralocorticoids on sodium-proton exchanger: genomic or nongenomic pathway? Am J Physiol. 1991;260:E719-E726
54. Wehling M. Looking beyond the dogma of genomic steroid action: insights and facts of the 1990s. J Mol Med. 1995;73:439-447